Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents

Authors

Asbiel Hasbum, The University of Texas Rio Grande Valley
Jaqueline Quintanilla, The University of Texas Rio Grande Valley
Juan Amieva, The University of Texas Rio Grande ValleyFollow
May-Hui Ding, The University of Texas Rio Grande Valley
Arkene Levy
Sue Anne Chew, The University of Texas Rio Grande Valley

Document Type

Article

Publication Date

2-2021

Abstract

Glioblastoma multiforme (GBM) is the most prevalent and aggressive form of glioma, with poor prognosis and high mortality rates. As GBM is a highly vascularized cancer, antiangiogenic therapies to halt or minimize the rate of tumor growth are critical to improving treatment. In this review, antiangiogenic therapies, including small-molecule drugs, nucleic acids and proteins and peptides, are discussed. The authors further explore biomaterials that have been utilized to increase the bioavailability and bioactivity of antiangiogenic factors for better antitumor responses in GBM. Finally, the authors summarize the current status of biomaterial-based targeting moieties that target endothelial cells in GBM to more efficiently deliver therapeutics to these cells and avoid off-target cell or organ side effects.

Comments

Copyright © 2021 Newlands Press

Recommended Citation

Hasbum, A., Quintanilla, J., Jr, J. A. A., Ding, M. H., Levy, A., & Chew, S. A. (2021). Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. Future medicinal chemistry, 13(4), 393–418. https://doi.org/10.4155/fmc-2020-0289

Publication Title

Future Med Chem

DOI

10.4155/fmc-2020-0289

Academic Level

faculty